Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin and Benzoyl Peroxide Gel, 1%|5%, a generic version of BenzaClin®1 Gel, 1%|5%, of Valeant Bermuda.
According to IQVIATM sales data for the 12 month period ending January 2019, the BenzaClin® Gel, 1%|5% market2 achieved annual sales of approximately $99.4 million*.
Glenmark's current portfolio consists of 151 products authorized for distribution in the U.S. marketplace and 53 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.630.7 as compared to the previous close of Rs. 633.55. The total number of shares traded during the day was 46395 in over 1368 trades.
The stock hit an intraday high of Rs. 645.75 and intraday low of 628.75. The net turnover during the day was Rs. 29528962.
1 All brand names and trademarks are the property of their respective owners.
2 Market includes brand and all available therapeutic equivalents
*IQVIATM National Sales Perspectives: Retail & Non-Retail, January 2019